Blueprint
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
Form 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of
1934
Date of Report (Date of earliest event reported): April 2,
2018
INNOVUS PHARMACEUTICALS, INC.
(Exact
name of registrant as specified in its charter)
|
Nevada
|
000-52991
|
90-0814124
|
|
(State
or other jurisdiction of incorporation)
|
(Commission
File
Number)
|
(IRS
Employer Identification No.)
|
|
8845 Rehco Road,
San Diego, CA
|
|
92122
|
|
(Address
of Principal Executive Offices)
|
|
(Zip
Code)
|
Registrant’s
telephone number, including area code: (858) 964-5123
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
☐
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
☐
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act
(17 CFR
240.14d-2(b))
☐
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange
Act (17 CFR
240.13e-4(c))
In this
report, “Innovus Pharmaceuticals,” “Innovus
Pharma,” “the Company”, “we,”
“us” and “our” refer to Innovus
Pharmaceuticals, Inc., and/or one or more of our wholly-owned
subsidiaries, unless the context otherwise provides. Innovus
Pharma® is a registered service mark of Innovus
Pharmaceuticals, Inc.
Item 2.02 – Results of Operations and Financial
Condition
On
April 2, 2018, the Company issued a press release reporting our
financial results for the year ended December 31, 2017 and
preliminary first quarter 2018 net revenue. The full text of the
press release is furnished as Exhibit 99.1 to this Current Report
on Form 8-K.
Item 9.01 – Financial Statements and Exhibits
(d) Exhibits
|
Exhibit Number
|
Description
|
|
|
Press release
issued April 2, 2018, reporting financial results for the year
ended December 31, 2017 and preliminary first
quarter 2018 net revenue
|
SIGNATURES
|
Date:
April 2, 2018
|
|
|
|
|
|
|
|
|
INNOVUS
PHARMACEUTICALS, INC.
|
|
|
|
|
|
|
|
By:
|
/s/
Bassam
Damaj
Bassam Damaj
President
and Chief Executive Officer
|
|
EXHIBIT
INDEX
|
Exhibit Number
|
Description
|
|
|
Press release
issued April 2, 2018, reporting financial results for the year
ended December 31, 2017 and preliminary first
quarter 2018 net revenue
|